ROMTech CEO Turned Down Revenue to Build Better Infrastructure
ROMTech CEO Peter Arn deliberately slowed revenue growth in 2025 to strengthen operations and clinical oversight. The medtech company served 57,000 patients with 34% YoY expansion by year-end, proving that controlled scaling in healthcare can outpace aggressive expansion.
In 2025, ROMTech faced a rare problem: demand that exceeded its capacity to deliver. The Connecticut medtech company manufactures the PortableConnect, a connected rehabilitation device that enables post-surgical patients to complete therapy at home while clinicians monitor progress remotely.
Instead of chasing every order, CEO Peter Arn made a deliberate choice to moderate revenue growth. The company continued expanding, but at a controlled pace—investing time to strengthen operational infrastructure and clinical oversight before scaling further. The trade-off was real: short-term revenue foregone in exchange for building systems capable of handling larger patient volumes.
The gamble worked. By 2025, ROMTech served over 57,000 patients and achieved 34% year-over-year growth, according to the company. "Sustainable growth in healthcare has to prioritize quality, safety and patient outcomes," Arn said. "In this industry, growing faster than your ability to deliver isn't ambition. It's risk."
Arn's strategy reflects a broader shift in home-based care. Hospital-at-home programs, remote patient monitoring, and virtual physical therapy have all expanded as health systems seek cost reduction and patients demand convenience. Rehabilitation is a natural fit: the therapy is frequent and repetitive, and traditionally required patients—many fresh from joint-replacement surgery—to travel to clinics multiple times weekly.
The friction point for home-based care is clinical supervision. Patients cannot complete meaningful rehabilitation without qualified oversight, and scaling that oversight remotely requires robust operational systems. Simply adding patients faster than you can hire and train clinicians is a path to patient safety incidents and regulatory scrutiny—a particularly acute risk in healthcare, where failure carries liability and reputational cost.
ROMTech's approach essentially inverted the typical scaling narrative. Most venture-backed companies prioritize speed to market share, accepting operational drag as a scaling problem to solve later. Arn's choice assumed that in healthcare, you don't get a second chance to fix safety. Slowing down to get the model right first was, by his logic, the faster path to sustainable scale.
Whether this strategy translates to favorable unit economics or a premium valuation remains unclear from available information. The decision to moderate growth is sound from an operational risk perspective, but only generates financial upside if the company can eventually capitalize on the demand it deferred without incurring new friction. If competitors enter the space and capture those deferred patients, Arn's caution becomes a missed window.
